161 related articles for article (PubMed ID: 8967967)
21. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Szumiel I
Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569
[TBL] [Abstract][Full Text] [Related]
22. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
23. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
Borovitskaya AE; D'Arpa P
Oncol Res; 1998; 10(5):271-6. PubMed ID: 9802062
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
25. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
Alessandri M; Beretta GL; Ferretti E; Mancia A; Khobta A; Capranico G
J Mol Biol; 2004 Mar; 337(2):295-305. PubMed ID: 15003448
[TBL] [Abstract][Full Text] [Related]
26. Oxidative DNA damage and repair in a cell lineage model of human proliferative breast disease (PBD).
Starcevic SL; Diotte NM; Zukowski KL; Cameron MJ; Novak RF
Toxicol Sci; 2003 Sep; 75(1):74-81. PubMed ID: 12805649
[TBL] [Abstract][Full Text] [Related]
27. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
30. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
31. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
32. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T
Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738
[TBL] [Abstract][Full Text] [Related]
33. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Menendez JA; Mehmi I; Lupu R
Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
[TBL] [Abstract][Full Text] [Related]
34. Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Sharma NK; Kumar A; Kumari A; Tokar EJ; Waalkes MP; Bortner CD; Williams J; Ehrenshaft M; Mason RP; Sinha BK
PLoS One; 2015; 10(11):e0141897. PubMed ID: 26540186
[TBL] [Abstract][Full Text] [Related]
35. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA.
Squires S; Ryan AJ; Strutt HL; Johnson RT
Cancer Res; 1993 May; 53(9):2012-9. PubMed ID: 7683249
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
[TBL] [Abstract][Full Text] [Related]
37. DNA repair, cell cycle progression and cell death following camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Skierski J; Szumiel I
Cell Biochem Funct; 1998 Dec; 16(4):239-52. PubMed ID: 9857486
[TBL] [Abstract][Full Text] [Related]
38. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
39. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
Nivens MC; Felder T; Galloway AH; Pena MM; Pouliot JJ; Spencer HT
Cancer Chemother Pharmacol; 2004 Feb; 53(2):107-15. PubMed ID: 14605862
[TBL] [Abstract][Full Text] [Related]
40. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer.
Li PX; Ngo D; Brade AM; Klamut HJ
Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]